Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 09, 2015 10:32 AM ET


Company Overview of Cadila Pharmaceuticals Limited

Company Overview

Cadila Pharmaceuticals Limited operates as a pharmaceutical company worldwide. The company develops branded and generic formulations for humans and animals; active pharmaceutical ingredients; biotechnology products and diagnostic kits; and plant tissue cultures. It also offers contract research and contract manufacturing services. The company offers its products for various therapeutic areas, including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives, antibiotics, respiratory, anti diabetics, immunologicals, antipyretics, anthelmintics, anti-hypertensives, anti-inflammatory preparations, antibacterials, vitamins, iron and protein tonics, and ophthalmology. It has a ...

Sarkhej-Dholka Road


Ahmedabad,  382210



91 27 1822 5001


91 27 1822 5039

Key Executives for Cadila Pharmaceuticals Limited

Chairman and Managing Director
Age: 55
Company Secretary
Compensation as of Fiscal Year 2015.

Cadila Pharmaceuticals Limited Key Developments

MicroCoal Technologies Inc. and Cadila Pharmaceuticals Limited Enter into Joint Venture Agreement for India

MicroCoal Technologies Inc. announced that it has signed a definitive investment agreement with an affiliate of Cadila Pharmaceuticals Limited and has entered into a joint venture agreement with Cadila for the Republic of India. Under the terms of the JV Agreement, MicroCoal and Cadila have agreed to form a corporation domiciled in India in which MicroCoal and Cadila will each hold a 50% interest. JVCO is expected to carry on its activities throughout India, and its key functions are planned to include: establishing and operating a testing/demonstration facility for the purpose of demonstrating the cost effectiveness of MicroCoal's technology to companies in the coal mining or coal-based electricity generation industries in India; marketing and promoting MicroCoal's technology throughout India; and developing one or more commercial-scale facilities in India based upon or incorporating MicroCoal's technology. Pursuant the JV Agreement, the parties have agreed to enter into an intellectual property license agreementwhereby MicroCoal will contribute its technology to JVCO by granting JVCO a fully paid up license to, among other things, research and develop and commercialize MicroCoal's intellectual property in India. The license agreement will permit JVCO to establish a testing/demonstration facility in India, utilize the MicroCoal trademark to market the technology in India and develop or sell commercial facilities. Closing of the Investment and the JV Agreement is subject to customary closing conditions, including receipt of any required regulatory approvals.

Cadila Pharmaceuticals (India) Launches Biosimilar Anti-Inflammatory Candidate in India

Cadila Pharmaceuticals (India) has launched a biosimilar version of AbbVie's (US) blockbuster medicine Humira (adalimumab). The biosimilar treatment, marketed under the product name Exemptia, has been approved by the Drug Control General for India for the management of inflammatory processes associated with autoimmune diseases; approved indicators include rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. Cadila is also seeking, and is likely to secure, approvals for Crohn's disease, psoriasis, and ulcerative colitis. Humira generated global sales worth USD 10.7 billion for AbbVie in 2013, an increase of 15% year on year. That growth trajectory is continuing to climb after the company secured additional indications globally. The anti-inflammatory drug is set to go off-patent in the US in December 2016 followed in April 2018 in the EU; although AbbVie would presumably defend its patent for more recently approved indications. In a statement Cadila said it is readying the biosimilar version for entry into the US market in 2019. At least eight other companies are in the race to launch a competitor medicine to Humira including Amgen (US) ABP 501, which recently reported positive Phase III trial results (seeUnited States: 9 October 2014:). Also in the pipeline is the Oncobiologics/Viropro (US) version of adalimumab known as ONS-3010; phase I clinical trials at the Center for Human Disease Research in Leiden are due to be completed by the end of 2014. Other promising adalimumab biosimilars that are under development include Sandoz's (Switzerland) GB2017 copy, which announced the start of Phase III clinical trials in December 2013. The trial to evaluate the efficacy, safety and immunogenicity of GB2017 regarding Humira in patients with moderate to severe chronic plague-type psoriasis is expected to be completed in June 2015. Cadila Pharmaceutical's copy of the adalimumab drug therapy will be administered as 40 mg subcutaneous injection once every alternate week with the treatment normally lasting six months.

NovaSAID AB Announces Strategic Partnership with Cadila Pharmaceuticals Limited to Develop Innovative Treatments in Inflammation and Pain Management

NovaSAID AB and Cadila Pharmaceuticals Ltd. announced a strategic partnership to develop new treatments for inflammation and pain in conditions such as rheumatoid arthritis. The companies will collaborate around preclinical and clinical development of drug candidates that have been developed by NovaSAID and the development will be onducted at Cadila Pharmaceuticals’ facility in Ahmedabad, India. According to the agreement, all revenue generated from the sale and marketing in India, Middle East and Africa of products covered by the agreement will be retained by Cadila and net sales in all other countries will be shared by the two companies. Cadila will bear all costs associated with the program through to Phase II. Many of the medical treatments for inflammation and pain are associated with unwanted side effects such as an increased risk for myocardial infarction and gastric ulcers. NovaSAID’s drug candidates targets an enzyme called microsomal prostaglandin E synthase -1 (mPGES-1), a critically important mediator of inflammation and pain, which theoretically should reduce the risk for side effects. The collaboration with Cadila will provide the resources to take this program into clinical development and further towards the market.

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cadila Pharmaceuticals Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at